News

The WIRB-Copernicus Group's (WCG) Clinical Services Division announces the acquisition of Analgesic Solutions, LLC, the global leader in the development of new pain medications and in…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, today resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and…
Read More...

Editas Medicine and BlueRock Therapeutics announced a strategic research collaboration and cross-licensing agreement to combine their respective genome editing and cell therapy…
Read More...

Dyne Therapeutics, a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases, launched with a $50 million Series A. Atlas Venture founded,…
Read More...

ViiV Healthcare presented three year results from the SWORD 1 & 2 studies, demonstrating that 84% (432/513) of participants who switched from their current three- or four-drug…
Read More...

Cellectis announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for…
Read More...

Clinical stage biotechnology company QUE Oncology announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot…
Read More...

BriaCell Therapeutics Corp. announced a clinical trial collaboration and supply agreement with Incyte, a global biopharmaceutical company focused on discovering and developing novel…
Read More...

Xencor, announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody…
Read More...

Novartis announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis in…
Read More...

Sangamo Therapeutics and Pfizer announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. Data indicate that SB-525…
Read More...

Pulmatrix announced its entry into a Binding Term Sheet with Cipla Technologies LLC, a subsidiary of Cipla Limited for the co-development and commercialization of Pulmazole (PUR1900) –…
Read More...

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused on…
Read More...

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) has granted…
Read More...

Amneal Pharmaceuticals announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that…
Read More...

Puma Biotechnology and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part…
Read More...

ProteoNic Biotechnology BV announced that it has licensed its 2G UNic technology for boosting recombinant protein production to the pharmaceutical company Bayer. Under the agreement,…
Read More...

Gilead Sciences announced HepConnect, a five-year, multi-million dollar initiative aimed at addressing the sharp increase in chronic hepatitis C (HCV) infections fueled by the nation’s…
Read More...

AstraZeneca has entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan…
Read More...

Barc Lab and OWL Metabolomics announced that they have entered into a global strategic partnership combining Barc Lab's industry leading central lab services with OWL Metabolomics'…
Read More...